Core Services

Dampier Salt agrees to sale of Lake Macleod operation to Leichhardt

Retrieved on: 
Monday, January 15, 2024

Dampier Salt Limited (Dampier Salt) has entered into a sales agreement for the Lake MacLeod salt and gypsum operation in Carnarvon, Western Australia, with privately-owned salt company Leichhardt Industrials Group (Leichhardt) for A$375 million (US$251 million).

Key Points: 
  • Dampier Salt Limited (Dampier Salt) has entered into a sales agreement for the Lake MacLeod salt and gypsum operation in Carnarvon, Western Australia, with privately-owned salt company Leichhardt Industrials Group (Leichhardt) for A$375 million (US$251 million).
  • Rio Tinto’s Managing Director Port, Rail & Core Services, Richard Cohen, said “The sale of Lake MacLeod will enable Dampier Salt to focus on enhancing operational efficiencies at its remaining two Pilbara operations, while allowing the new owner of Lake MacLeod to maximise its potential.
  • “Until the completion of the sale, the Dampier Salt leadership team’s focus will be on safety, delivering on plan, and maintaining respect for all people at Lake MacLeod and in the Carnarvon community.
  • “We are pleased Leichhardt has committed to retaining all Lake MacLeod employees, ensuring continuity of operation and providing job stability to the 130-strong workforce.”
    Lake MacLeod is one of three solar salt sites owned by Dampier Salt, which also includes operations in Dampier and Port Hedland.

AscellaHealth Provides Specialty & Rare Pipeline Digest™ Recap: Navigating the Path to 2024 Groundbreaking Therapies

Retrieved on: 
Tuesday, January 9, 2024

AscellaHealth , a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics.

Key Points: 
  • AscellaHealth , a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240109714340/en/
    “This timely, thoroughly researched document provides valuable insights and data to fortify our partnerships, assist our clients and support the entire specialty pharmaceutical ecosystem,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth.
  • “As we closed out 2023 and stepped into 2024, this issue becomes a compass, empowering stakeholders to proactively navigate the evolving landscape.

Bob Nicholas Promoted to Vice President of Marketing & Sales Enablement at Amerisure

Retrieved on: 
Wednesday, November 1, 2023

FARMINGTON HILLS, Mich., Nov. 1, 2023 /PRNewswire-PRWeb/ -- Amerisure is pleased to announce the promotion of Bob Nicholas to Vice President of Marketing & Sales Enablement. In this role, Mr. Nicholas will oversee the strategic development and execution of Amerisure's marketing, communication and branding activities, as well as lead the sales enablement and agency services functions.

Key Points: 
  • Amerisure is pleased to announce the promotion of Bob Nicholas to Vice President of Marketing & Sales Enablement.
  • FARMINGTON HILLS, Mich., Nov. 1, 2023 /PRNewswire-PRWeb/ -- Amerisure is pleased to announce the promotion of Bob Nicholas to Vice President of Marketing & Sales Enablement.
  • In this role, Mr. Nicholas will oversee the strategic development and execution of Amerisure's marketing, communication and branding activities, as well as lead the sales enablement and agency services functions.
  • To further advance the sales academy and sales enablement functions, he was promoted to Assistant Vice President, Sales Enablement & Customer Experience in 2022.

AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies

Retrieved on: 
Thursday, September 28, 2023

AscellaHealth , a global healthcare and specialty pharmacy solutions organization, today released its Q3 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics.

Key Points: 
  • AscellaHealth , a global healthcare and specialty pharmacy solutions organization, today released its Q3 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics.
  • We applaud the relentless efforts of pharmaceutical manufacturers in developing and introducing these groundbreaking therapies.
  • Our collaboration with all stakeholders ensures that these advancements translate into improved treatment access, patient care and outcomes."
  • AscellaHealth is a single-source partner providing end-to-end, global solutions which result in the streamlined commercialization of specialty drugs, cost savings for clients and an optimal treatment journey for the rare disease / specialty population.

McLean & Company Responds to Changes in the HR Landscape With New HR Management and Governance Framework and Diagnostic Tools

Retrieved on: 
Wednesday, September 13, 2023

These updated diagnostics include the HR Management & Governance (HRMG) Diagnostic and the HR Organizational Alignment (HROA) Diagnostic survey tools.

Key Points: 
  • These updated diagnostics include the HR Management & Governance (HRMG) Diagnostic and the HR Organizational Alignment (HROA) Diagnostic survey tools.
  • McLean and Company's HR Management and Governance Framework establishes a research-informed, holistic model of HR.
  • To take advantage of the full resource bundle, HR professionals can access the updated HR Management & Governance (HRMG) Framework , the HR Management & Governance (HRMG) Diagnostic survey tool , and the HR Organizational Alignment (HROA) Diagnostic survey tool .
  • McLean & Company is also pleased to offer the HR Management & Governance (HRMG) Diagnostic Guide and the HR Organizational Alignment (HROA) Diagnostic Guide to support the understanding and application of the diagnostic survey tools.

Teleperformance: First-half 2023 Results

Retrieved on: 
Wednesday, July 26, 2023

The North America & Asia-Pacific region generated EBITA before non-recurring items of €140 million in first-half 2023, compared with €134 million in the prior-year period.

Key Points: 
  • The North America & Asia-Pacific region generated EBITA before non-recurring items of €140 million in first-half 2023, compared with €134 million in the prior-year period.
  • EBITA before non-recurring items in the EMEA region came to €110 million in first‑half 2023, versus €127 million in first-half 2022, yielding a margin of 8.8% versus 9.4% one year earlier.
  • Teleperformance has maintained its financial flexibility, with leverage of ~1.8x proforma 2023 EBITDA and a BBB credit rating.
  • As of June 30, 2023, 72 countries have received Great Place to Work® (GPTW®) certifications, up eight countries from 2022.

TLPFY DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Teleperformance SE Investors with Losses in Excess of $50K to Secure Counsel Before Important June 20 Deadline in Securities Class Action – TLPFY

Retrieved on: 
Tuesday, June 20, 2023

WHAT TO DO NEXT: To join the Teleperformance class action, go to https://rosenlegal.com/submit-form/?case_id=15278 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Teleperformance class action, go to https://rosenlegal.com/submit-form/?case_id=15278 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than June 20, 2023.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

DEADLINE ALERT for UP, TLPFY, HBNC, and TSE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, June 19, 2023

LOS ANGELES, June 19, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, June 19, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

TELEPERFORMANCE SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Teleperformance To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, June 17, 2023

If you suffered losses exceeding $100,000 investing in Teleperformance stock or options between July 29, 2020 and November 9, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Teleperformance stock or options between July 29, 2020 and November 9, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Teleperformance conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teleperformance SE (TLPFY)

Retrieved on: 
Friday, June 16, 2023

The Law Offices of Frank R. Cruz reminds investors of the upcoming June 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Teleperformance SE (“Teleperformance” or the “Company”) (OTC: TLPFY ) American Depositary Receipts (“ADRs”) between July 29, 2020 and November 9, 2022, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming June 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Teleperformance SE (“Teleperformance” or the “Company”) (OTC: TLPFY ) American Depositary Receipts (“ADRs”) between July 29, 2020 and November 9, 2022, inclusive (the “Class Period”).
  • If you purchased or otherwise acquired Teleperformance ADRs during the Class Period, you may move the Court no later than June 20, 2023 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.